International Clinical Trial: Efficacy and Safety of Inebilizumab in the Treatment of Relapsing Neuromyelitis Optica Spectrum Disorder : A Multicenter, Randomized Controlled, Open-Label Study

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119728) titled 'Efficacy and Safety of Inebilizumab in the Treatment of Relapsing Neuromyelitis Optica Spectrum Disorder : A Multicenter, Randomized Controlled, Open-Label Study' on March 3.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Affiliated Provincial Hospital of Shandong First Medical University (Shandong Provincial Hospital)

Condition: Neuromyelitis Optica Spectrum Disorder

Intervention: Inebilizumab treatment group:Inebilizumab treatment (intravenous infusion of 300 mg on day 1, repeated intravenous infusion of 300 mg on day 15 subsequent intravenous infusion of 300 mg every 6 months ...